BCL2 and ovarian carcinoma: A growing body of researches has revealed the association of Bcl‐2 with chemoresistance, and the Bcl‐2 family has been proposed as a potential therapeutic target.9 For instance, Dai et al10 unraveled that Bcl‐2 protein can effectively curb ovarian cancer cell apoptosis through resistance to cisplatin.